Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer
Shots:
- The P-III MONARCH 2 study involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 pre/peri- and postmenopausal women in a ratio (2:1) with HR+- HER2- metastatic breast cancer whose cancer progressed following endocrine therapy
- The P-III MONARCH 2 study resulted in meetings 2EP of overall survival with no new observed safety signals. The P-III MONARCH study previously met its 1EPs i.e- improvement in PFS which serves as the basis for its approval in 50+ countries
- Verzenio is a CDK 4 & 6 inhibitors which are activated by binding to D-cyclins- inhibiting Rb phosphorylation with blocking progression from G1 to S phase of the cell cycle resulting in senescence and apoptosis
Click here to read full press release/ article
Ref: Eli Lilly | Image: Eli Lilly
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com